Pay in 4 interest-free payments of $8.00 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
PHF8 at IC50 ~0
345(1):25-31
InChi: InChI=1S/C14H11N3O/c18-14(10-4-2-1-3-5-10)17-13-8-11-6-7-15-12(11)9-16-13/h1-9
N106 treatment increases contractile properties of cultured rat cardiomyocytes and significantly improves ventricular function in mice with heart failure
It acts to stabilize HIF-1α expression at normal oxygen tensions in cultured cells
ABT-199 - BCL-2 inhibitor. CAS# 1257044-40-8 Catalog No.:M60075-10S PHF8 at IC50 ~0ABT 199, CAS No. 1257044 40 8, is a highly potent, selective, and orally bioavailable BCL 2 inhibitor. ABT 199 has picomolar affinity for BCL 2 (Ki < 0. 010 nM) and > 1000 folds selectivity over BCL XL (Ki = 48 nM) and BCL W (Ki = 245 nM). Therefore, ABT 199 is a much improved lead compound over the original ABT 263 (navitoclax) to avoid thrombocytopenia caused by BCL XL inhibition. ABT 199s cell killing effect is selective and mechanism dependent. It